BioMarin Pharmaceuticals BMRN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.31B+39.1% | $942.84M+24.9% | $755.13M+4.2% | $724.53M+23.4% | ||
| $248.93M+27.7% | $194.86M-38.9% | $318.68M-43.8% | $567.01M+32.9% | ||
| $908.21M+37.5% | $660.54M+4.2% | $633.7M+37.4% | $461.32M+23.5% | ||
| $1.3B+5.4% | $1.23B+11.3% | $1.11B+23.8% | $894.08M+15.1% | ||
| $106.51M-31.0% | $154.34M-0.9% | $155.7M+18.8% | $131.07M+63.3% | ||
| $801.06M+45.5% | $550.68M-3.6% | $571.11M+39.1% | $410.66M-1.1% | ||
| $391.31M-25.8% | $527.63M+38.7% | $380.37M+8.0% | $352.36M+25.3% | ||
| $185.78M-7.8% | $201.53M+42.5% | $141.39M+35.3% | $104.52M-5.4% | ||
| $3.95B+22.3% | $3.23B+9.3% | $2.96B+7.4% | $2.75B+21.0% | ||
| $952.51M-8.7% | $1.04B-2.2% | $1.07B-0.7% | $1.07B+3.7% | ||
| $1.07B+20.5% | $891.79M+2.8% | $867.09M+8.1% | $802.15M+11.3% | ||
| $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | $196.2M0.0% | ||
| $213.84M-16.2% | $255.28M-13.4% | $294.7M-13.0% | $338.57M-12.9% | ||
| $1.51B+1.3% | $1.49B-3.7% | $1.55B+2.7% | $1.51B+3.8% | ||
| $277.05M+10.2% | $251.39M+46.6% | $171.54M-2.7% | $176.24M+15.9% | ||
| $492.24M-5.6% | $521.24M-14.7% | $611.14M+83.1% | $333.84M-34.3% | ||
| $7.59B+8.7% | $6.99B+2.2% | $6.84B+7.3% | $6.38B+6.2% | ||
| $759.03M+25.0% | $606.99M-11.1% | $683.15M+19.2% | $572.96M+15.0% | ||
| $219.42M+8.3% | $202.51M+0.7% | $201.07M-3.1% | $207.57M+1.5% | ||
| $3.67M-70.8% | $12.57M+374% | $2.65M-83.6% | $16.21M+1,237% | ||
| $907K— | —— | —— | —— | ||
| $759.03M+25.0% | $606.99M-48.4% | $1.18B+99.9% | $588.88M+7.8% | ||
| $597.18M— | —— | —— | —— | ||
| $150.82M+17.1% | $128.82M+7.4% | $119.94M+19.9% | $100.02M+1.7% | ||
| $1.51B+13.2% | $1.33B-29.6% | $1.89B+6.7% | $1.77B+1.9% | ||
| 500M+261,680% | 191K+1.1% | 189K+1.6% | 186K+1.1% | ||
| $5.96B+2.7% | $5.8B+3.4% | $5.61B+3.8% | $5.4B+4.1% | ||
| $154.21M+179% | -$194.7M+68.7% | -$621.55M+21.2% | -$789.2M+15.2% | ||
| -$13.47M-122% | $61.65M+314% | -$28.79M-644% | -$3.87M-127% | ||
| $6.09B+7.6% | $5.66B+14.3% | $4.95B+7.6% | $4.6B+7.9% | ||
| $7.59B+8.7% | $6.99B+2.2% | $6.84B+7.3% | $6.38B+6.2% | ||
| $2.05B+23.6% | $1.66B-1.6% | $1.68B+2.6% | $1.64B+7.7% | ||
| $2.05B+23.7% | $1.66B-1.5% | $1.68B+3.7% | $1.63B+6.8% | ||
| $248.93M+27.7% | $194.86M-38.9% | $318.68M-43.8% | $567.01M+32.9% | ||
| $391.31M-25.8% | $527.63M+38.7% | $380.37M+8.0% | $352.36M+25.3% | ||
| $185.78M-7.8% | $201.53M+42.5% | $141.39M+35.3% | $104.52M-5.4% | ||
| $25.66M-67.8% | $79.64M+779% | $9.07M-60.6% | $23M+1.0% | ||
| $277.05M+10.2% | $251.39M+46.6% | $171.54M-2.7% | $176.24M+15.9% | ||
| $723.97M+0.4% | $721.11M+1.6% | $710.01M+2.8% | $690.87M+2.0% | ||
| $2.05B+23.6% | $1.66B-1.6% | $1.68B+2.6% | $1.64B+7.7% | ||
| $492.24M-5.6% | $521.24M-14.7% | $611.14M+83.1% | $333.84M-34.3% | ||
| $1.51B+1.3% | $1.49B-3.7% | $1.55B+2.7% | $1.51B+3.8% | ||
| $213.84M-16.2% | $255.28M-13.4% | $294.7M-13.0% | $338.57M— | ||
| $213.84M-16.2% | $255.28M-13.4% | $294.7M-13.0% | $338.57M-12.9% | ||
| $277.05M+10.2% | $251.39M+46.6% | $171.54M-2.7% | $176.24M+15.9% | ||
| $2.03B+4.8% | $1.93B+0.1% | $1.93B+3.1% | $1.88B+6.8% | ||
| $277.05M+10.2% | $251.39M+46.6% | $171.54M-2.7% | $176.24M+15.9% | ||
| $312.77M+32.9% | $235.4M-25.4% | $315.51M+36.4% | $231.24M+15.8% | ||
| $219.42M+8.3% | $202.51M+0.7% | $201.07M-3.1% | $207.57M+1.5% | ||
| $7.97M+0.6% | $7.92M-44.6% | $14.3M+7.5% | $13.31M-12.5% | ||
| $759.03M+25.0% | $606.99M-11.1% | $683.15M+19.2% | $572.96M+15.0% | ||
| $3.67M-70.8% | $12.57M+374% | $2.65M-83.6% | $16.21M— | ||
| $31.01M+137% | $13.06M-61.4% | $33.85M+169% | $12.6M+101% | ||
| $219.42M+8.3% | $202.51M+0.7% | $201.07M-3.1% | $207.57M+1.5% | ||
| $31.01M+137% | $13.06M-61.4% | $33.85M+169% | $12.6M+101% | ||
| $576.27M— | —— | —— | —— | ||
| $7.68M+7.9% | $7.12M+15.0% | $6.19M-31.2% | $9M+48.9% | ||
| $642.87M+1,556% | $38.83M-92.8% | $540.78M+1,366% | $36.89M-16.7% | ||
| —— | —— | —— | —— | ||
| $10.51M-6.4% | $11.23M+13.9% | $9.86M+11.3% | $8.86M-8.6% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 192.3M+0.8% | 190.8M+1.1% | 188.6M+1.3% | 186.3M+1.3% | ||
| $5.96B+2.7% | $5.8B+3.4% | $5.61B+3.8% | $5.4B+4.1% | ||
| $192K+0.5% | $191K+1.1% | $189K+1.6% | $186K+1.1% | ||
| $4.9M+56.5% | $3.13M-28.6% | $4.39M+2,660% | $159K-77.9% | ||
| $8K-99.0% | $767K-76.5% | $3.27M-79.5% | $15.93M+532% | ||
| $2.05B+23.6% | $1.66B-1.6% | $1.68B+2.6% | $1.64B+7.7% | ||
| $40.91M+162% | $15.59M-62.9% | $42.02M+207% | $13.68M+79.0% | ||
| $40.91M+162% | $15.59M-62.9% | $42.02M+207% | $13.68M+79.0% | ||
| $166.93M+38.1% | $120.84M+25.6% | $96.18M+32.4% | $72.65M+51.4% | ||
| $7.97M+0.6% | $7.92M-44.6% | $14.3M+7.5% | $13.31M-12.5% | ||
| $8K-99.0% | $767K-76.5% | $3.27M-79.5% | $15.93M+532% | ||
| $4.9M+56.5% | $3.13M-28.6% | $4.39M+2,660% | $159K-77.9% | ||
| $2.05B+23.6% | $1.66B-1.6% | $1.68B+2.6% | $1.64B+7.7% | ||
| $2.05B+23.7% | $1.66B-1.5% | $1.68B+3.7% | $1.63B+6.8% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | ||
| $500M0.0% | $500M0.0% | $500M0.0% | $500M0.0% | ||
| $192.3M+0.8% | $190.76M+1.1% | $188.6M+1.3% | $186.25M+1.3% | ||
| $192.3M+0.8% | $190.76M+1.1% | $188.6M+1.3% | $186.25M+1.3% | ||
| —— | —— | —— | —— | ||
| $576.27M— | —— | —— | —— | ||
| $25.66M-67.8% | $79.64M+779% | $9.07M-60.6% | $23M+1.0% | ||
| $40.91M+162% | $15.59M-62.9% | $42.02M+207% | $13.68M+79.0% | ||
| $510.13M+9.5% | $465.83M+12.2% | $415.31M+17.9% | $352.3M+22.0% | ||
| $723.97M+0.4% | $721.11M+1.6% | $710.01M+2.8% | $690.87M+2.0% | ||
| $8.69M+14.7% | $7.57M-13.7% | $8.78M-15.4% | $10.38M-0.9% | ||
| —— | —— | —— | —— | ||
| $0— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioMarin Pharmaceuticals's total assets?
- BioMarin Pharmaceuticals (BMRN) holds $8.6B in total assets, up 20.2% year over year.
- How much debt does BioMarin Pharmaceuticals have?
- BioMarin Pharmaceuticals carries $1.4B in total debt against $6.2B of shareholders' equity, a debt-to-equity ratio of 0.23.
- How much cash does BioMarin Pharmaceuticals have?
- BioMarin Pharmaceuticals holds $3.1B in cash and equivalents.
- Can BioMarin Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.81 — current assets exceed current liabilities.
- Where does BioMarin Pharmaceuticals's balance sheet data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
